ARID1A and non-small cell lung carcinoma: Outside of the EGFR comutation context, the opposite has been observed, with several studies reporting an association between ARID1A alterations and longer PFS and OS following treatment with ICI, not just in NSCLC but across a range of cancers [13, 44, 49].